Streptococcal B vaccine - Emergent BioSolutions

Drug Profile

Streptococcal B vaccine - Emergent BioSolutions

Alternative Names: EBS-A42; EBS-C12; GBS vaccine - Emergent BioSolutions

Latest Information Update: 03 Mar 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Emergent BioSolutions
  • Class Streptococcal vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Streptococcal infections

Most Recent Events

  • 29 Dec 2006 Clinical data added to the adverse events and Bacterial Infections immunogenicity sections
  • 27 Jun 2005 Microscience has been acquired by Emergent BioSolutions
  • 31 Dec 2003 Phase-I clinical trials in Streptococcal infections in United Kingdom (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top